These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

117 related items for PubMed ID: 1541935

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Abnormal serum bone Gla protein levels in multiple myeloma. Crucial role of bone formation and prognostic implications.
    Bataille R, Delmas PD, Chappard D, Sany J.
    Cancer; 1990 Jul 01; 66(1):167-72. PubMed ID: 2354403
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Osteocalcin is not a marker of progress in multiple myeloma. Le Groupe d'Etude et de Recherche sur le Myélome (GERM).
    Mejjad O, Le Loët X, Basuyau JP, Ménard JF, Jego P, Grisot C, Daragon A, Grosbois B, Euller-Ziegler L, Monconduit M.
    Eur J Haematol; 1996 Jul 01; 56(1-2):30-4. PubMed ID: 8599990
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Serum bone sialoprotein as a marker of tumour burden and neoplastic bone involvement and as a prognostic factor in multiple myeloma.
    Woitge HW, Pecherstorfer M, Horn E, Keck AV, Diel IJ, Bayer P, Ludwig H, Ziegler R, Seibel MJ.
    Br J Cancer; 2001 Feb 02; 84(3):344-51. PubMed ID: 11161399
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Procollagen I amino-terminal propeptide as a potential marker for multiple myeloma.
    Kowalska M, Druzd-Sitek A, Fuksiewicz M, Kotowicz B, Chechlinska M, Syczewska M, Walewski J, Kaminska J.
    Clin Biochem; 2010 Apr 02; 43(6):604-8. PubMed ID: 20045402
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Plasma monomeric calcitonin as a marker of disease activity in multiple myeloma patients with osteolysis.
    Monti M, Scazzoso A, Bevilacqua M, Santi I, D'Aprile E, Saligari A, Norbiato G, Cunietti E.
    Int J Biol Markers; 1992 Apr 02; 7(2):87-92. PubMed ID: 1634826
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Factors affecting outcome of patients with multiple myeloma.
    Basit A, Siddiqui N, Hameed A, Muzaffar N, Athar S.
    J Ayub Med Coll Abbottabad; 2014 Apr 02; 26(3):376-9. PubMed ID: 25671952
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Prognostic factors in IgG and micromolecular multiple myeloma. Retrospective analysis of 50 consecutive cases].
    Pasqualetti P, Casale R, Colantonio D, Festuccia V, Di Lauro G, Natali G.
    Minerva Med; 1987 May 15; 78(9):603-8. PubMed ID: 3587727
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.